Transformation of polycythemia vera to chronic myelogenous leukemia

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 11, 2007, Pages 1719-1724

  Mirza, Imran ^a   Frantz, Christine ^a   Clarke, Gwendolyn ^a   Voth, Arnold J ^a   Turner, Robert ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2;

ABL1 GENE; AGED; ARTICLE; BCR GENE; BLOOD SAMPLING; BONE MARROW BIOPSY; BONE MARROW CELL; CASE REPORT; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EDEMA; FEMALE; GENE; GENE FUSION; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; PATHOGENESIS; PLEURA EFFUSION; POLYCYTHEMIA VERA; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; POLYCYTHEMIA VERA;

EID: 35948953490     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005;434:1144-1148.
2. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
7. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol. 1992;48:20-26.
8. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15:173-189.
9. Najean Y, Deschamps A, Dresch C, Daniel MT, Rain JD, Arrago JP. Acute leukemia and myelodysplasia in polycythemia vera: a clinical study with long-term follow-up. Cancer. 1988;61:89-95.
10. Lugassy G, Farhi R. Chronic neutrophilic leukemia associated with polycythemia vera. Am J Hematol. 1989;31:300-301.
11. Iurlo A, Foa P, Maiolo AT, Luksch R, Capsoni F, Polli EE. Polycythemia vera terminating in chronic neutrophilic leukemia: report of a case. Am J Hematol. 1990;35:139-140.
12. Foa P, Iurlo A, Saglio G, Guerrasio A, Capsoni F, Maiolo AT. Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach. Br J Haematol. 1991;78:286-288.
13. Higuchi T, Oba R, Endo M, et al. Transition of polycythemia vera to chronic neutrophilic leukemia. Leuk Lymphoma. 1999;33:203-206.
14. Kemp NH, Stafford JL, Tanner T. Chromosome studies during early and terminal chronic myeloid leukaemia. Br Med J. 1964;5389:1010-1014.
15. Koulischer L, Fruhling J, Henry J. Cytogenetic findings in Vaquez' disease. Eur J Cancer. 1967;3:193-201.
16. Hoppin EC, Lewis JP. Polycythemia rubra vera progressing to Ph-positive chronic myelogenous leukemia. Ann Intern Med. 1975;83:820-823.
17. Haq AU. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol. 1990;35:110-113.
18. Jantunen E, Nousiainen T. Ph-positive chronic myelogenous leukemia evolving after polycythemia vera. Am J Hematol. 1991;37:212.
19. Roth AD, Oral A, Przepiorka D, Gollin SM, Chervenick PA. Chronic myelogenous leukemia and acute lymphoblastic leukemia occurring in the course of polycythemia vera. Am J Hematol. 1993;43:123-128.
20. Ganti AK, Potti A, Mehdi SA. Chromosomal anomalies in two coexistent myeloproliferative disorders. Cancer Genet Cytogenet. 2003;145:172-175.
21. Saviola A, Fiorani C, Ferrara L, et al. Transition of polycythemia vera to chronic myeloid leukaemia. Eur J Haematol. 2005;75:264-266.
22. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-1132.
23. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature (1995). Basel, Switzerland: S Karger; 1995.
24. Kohler S, Galili N, Sklar JL, Donlon TA, Blume KG, Cleary ML. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia. Leukemia. 1990;4:541-547.
25. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
26. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
27. Jelinek J, Oki Y, Gharihyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
28. Kronenwett R, Graf T, Neumann F, et al. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis. Leuk Res. 2006;30:1323-1324.
29. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631-635.
30. Wahlin A, Golovleva I. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. Eur J Haematol. 2003;70:240-241.
31. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol. 2005;128:734-736.
32. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-2921.
33. Aguiar RC. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma. 1998;29:17-26.
34. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941-1949.
35. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia. 2003;17:465-467.
36. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17:481-487.
37. Aviram A, Blickstein D, Stark P, et al. Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma. 1999;33:77-82.
38. Hsu HC, Tan LY, Au LC, et al. Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia. J Lab Clin Med. 2004;143:125-129.
39. Vickers M. Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol. 1996;94:1-4.
40. Mauro MJ, Loriaux M, Deininger MW. Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia. 2004;18:1305-1307.